Linked Life Data

18203308

Source:http://linkedlifedata.com/resource/pubmed/id/18203308

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2008-3-6
pubmed:abstractText
We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept. Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively. On colonoscopy, inflammatory lesions highly compatible with CD were found endoscopically and histologically in all patients. Etanercept was stopped, and CD responded well to standard treatment. One of the 3 patients was reexposed to etanercept later on. While the 2 patients without re-exposure to etanercept did not have further CD flares, the third patient flared 6 months after re-institution of etanercept in combination with azathioprine. New onset of CD may be considered as an immune-mediated injury induced by etanercept. Although this is an intriguing hypothesis, any causative role of etanercept remains unproven at this stage.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0315-162X
pubmed:author
pubmed:issnType
Print
pubmed:volume
35
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
532-6
pubmed:dateRevised
2009-1-14
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.
pubmed:affiliation
Department of Rheumatology, Division of Medicine, and Institute for Pathology/Research Center ImmunoSciences (RCIS), Charité Medical University, Campus Benjamin Franklin, Berlin, Germany.
pubmed:publicationType
Journal Article, Case Reports